Atea Pharmaceuticals, Inc. - Common Stock (AVIR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AVIR on Nasdaq
Shares outstanding
78,888,889
Price per share
$3.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
56,760,694
Total reported value
$202,609,064
% of total 13F portfolios
0%
Share change
+3,792,323
Value change
+$13,983,097
Number of holders
110
Price from insider filings
$3.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atea Pharmaceuticals, Inc. - Common Stock (AVIR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +70% $29,470,003 +$10,937,987 9,095,680 +59% FMR LLC 28 Nov 2025
Sommadossi Jean-Pierre 10% $26,185,536 8,876,453 Jean-Pierre Sommadossi 31 Mar 2025
BML Investment Partners, L.P. 9.9% +16% $27,881,700 +$2,119,466 7,810,000 +8.2% Leonard Braden Michael 31 Dec 2025
BlackRock, Inc. 7.1% $17,942,932 6,082,350 BlackRock, Inc. 31 Mar 2025
Radoff Bradley Louis 4% +10% $9,971,295 +$811,250 3,380,100 +8.9% Radoff Bradley Louis 16 Apr 2025
EcoR1 Capital, LLC 4% $9,857,876 3,341,653 EcoR1 Capital, LLC 31 Dec 2024

As of 31 Dec 2025, 110 institutional investors reported holding 56,760,694 shares of Atea Pharmaceuticals, Inc. - Common Stock (AVIR). This represents 72% of the company’s total 78,888,889 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Atea Pharmaceuticals, Inc. - Common Stock (AVIR) together control 67% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 12% 9,678,996 +66% 0% $34,554,015
BlackRock, Inc. 11% 8,491,202 +0.38% 0% $30,313,592
BML Capital Management, LLC 9.5% 7,490,000 0% 24% $26,739,300
TANG CAPITAL MANAGEMENT LLC 6.1% 4,814,700 -0.24% 0.85% $17,188,479
VANGUARD GROUP INC 5.4% 4,227,110 -10% 0% $15,090,783
Bain Capital Life Sciences Investors, LLC 3.2% 2,485,638 0% 0.68% $8,873,728
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,841,001 -3.1% 0% $6,573,860
STATE STREET CORP 2.3% 1,784,467 +0.03% 0% $6,370,547
DIMENSIONAL FUND ADVISORS LP 1.7% 1,373,946 -11% 0% $4,904,865
JPMORGAN CHASE & CO 1.7% 1,348,294 +119% 0% $4,813,410
ACADIAN ASSET MANAGEMENT LLC 1.7% 1,303,904 +34% 0.01% $4,651,000
RENAISSANCE TECHNOLOGIES LLC 1.5% 1,188,500 -3.2% 0.01% $4,242,945
TWO SIGMA ADVISERS, LP 1.3% 1,059,700 +33% 0.01% $3,783,129
TWO SIGMA INVESTMENTS, LP 0.94% 745,415 +58% 0% $2,661,132
MILLENNIUM MANAGEMENT LLC 0.88% 698,156 +43% 0% $2,492,417
MORGAN STANLEY 0.83% 656,075 +46% 0% $2,342,187
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.77% 607,792 -2.8% 0% $2,169,817
NORTHERN TRUST CORP 0.71% 560,218 -12% 0% $1,999,978
GOLDMAN SACHS GROUP INC 0.6% 472,522 +39% 0% $1,686,904
D. E. Shaw & Co., Inc. 0.59% 464,787 +27% 0% $1,659,289
Peapod Lane Capital LLC 0.55% 435,020 -4.9% 1.3% $1,553,021
CM Management, LLC 0.45% 355,000 -29% 1.1% $1,267,350
BANQUE PICTET & CIE SA 0.44% 345,077 0% 0.01% $1,231,925
JANE STREET GROUP, LLC 0.32% 250,705 +31% 0% $895,017
BARCLAYS PLC 0.31% 242,990 +0.63% 0% $867,474

Institutional Holders of Atea Pharmaceuticals, Inc. - Common Stock (AVIR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 56,760,694 $202,609,064 +$13,983,097 $3.57 110
2025 Q3 53,140,830 $154,099,223 +$874,820 $2.90 112
2025 Q2 52,688,325 $189,687,193 -$496,611 $3.60 105
2025 Q1 52,943,893 $158,295,789 -$11,408,006 $2.99 102
2024 Q4 56,328,149 $188,651,399 -$6,772,701 $3.35 103
2024 Q3 57,907,511 $193,998,567 +$4,533,749 $3.35 105
2024 Q2 56,687,549 $187,637,646 +$7,123,002 $3.31 101
2024 Q1 54,332,807 $219,504,800 -$1,664,806 $4.04 112
2023 Q4 55,088,379 $168,248,591 -$1,691,841 $3.05 106
2023 Q3 56,849,245 $170,555,234 -$2,209,314 $3.00 117
2023 Q2 57,041,241 $213,289,848 +$971,494 $3.74 131
2023 Q1 56,778,720 $190,176,002 -$5,878,803 $3.35 128
2022 Q4 57,878,556 $278,395,526 -$5,016,357 $4.81 130
2022 Q3 57,466,718 $326,999,436 -$1,731,457 $5.69 115
2022 Q2 57,566,762 $408,727,109 +$19,469,875 $7.10 122
2022 Q1 54,946,542 $396,539,427 +$6,369,699 $7.22 121
2021 Q4 53,581,427 $478,985,081 -$368,375,568 $8.94 134
2021 Q3 56,840,788 $1,992,582,650 -$21,707,203 $35.06 137
2021 Q2 58,896,806 $1,265,508,812 +$160,923,836 $21.48 100
2021 Q1 47,389,412 $2,914,493,173 +$30,510,569 $61.75 78
2020 Q4 49,910,976 $2,070,766,859 +$1,819,869,860 $41.78 69